Literature DB >> 24125136

The burden of illness in patients with hereditary angioedema.

Aleena Banerji1.   

Abstract

OBJECTIVE: Hereditary angioedema (HAE) is a rare genetic disease characterized by long-term recurrent attacks of subcutaneous or submucosal edema in different parts of the body. A comprehensive review of the literature on burden of illness for patients with HAE is presented. DATA SOURCES: A Boolean search was performed using MEDLINE and EMBASE databases and the Internet. STUDY SELECTION: Articles discussing aspects of the burden of illness in HAE were selected. Topics focused on the course of the disease, nature of attacks, treatment, quality of life, and costs.
RESULTS: Hereditary angioedema is associated with a significant and multifaceted disease burden. Diagnosis is often delayed for years, with patients receiving ineffective treatment and unnecessary medical procedures before diagnosis. HAE attacks are painful, unpredictable, and debilitating and often require emergency medical attention. Attacks can affect a patient's daily activities, including work or schooling. Depression and anxiety are prevalent in patients with HAE. Recent advances in treatment provide patients with effective and well-tolerated prophylactic and on-demand therapeutic options. However, end points specific to HAE that better measure the impact of treatment on disease burden are lacking. Furthermore, there is a notable paucity of literature directed toward physicians who are instrumental in diagnosing and treating patients with HAE (eg, emergency department).
CONCLUSION: More publications are broadening the understanding of HAE. However, important gaps remain. Effective management of HAE requires a more comprehensive understanding of the disease burden so that disease management can be individualized to meet specific patient needs.
Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125136     DOI: 10.1016/j.anai.2013.08.019

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  18 in total

1.  Current state of hereditary angioedema management: a patient survey.

Authors:  Aleena Banerji; Paula Busse; Sandra C Christiansen; Henry Li; William Lumry; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony Castaldo; Janet F Long; Bruce L Zuraw; Marc Riedl
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

2.  Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema.

Authors:  Ting Qiu; Maria J Chiuchiolo; Adele S Whaley; Anthony R Russo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Odelya E Pagovich
Journal:  Allergy       Date:  2019-03-19       Impact factor: 13.146

3.  Perceived economic burden associated with an inherited cardiac condition: a qualitative inquiry with families affected by arrhythmogenic right ventricular cardiomyopathy.

Authors:  Holly Etchegary; Glenn Enright; Rick Audas; Daryl Pullman; Terry-Lynn Young; Kathy Hodgkinson
Journal:  Genet Med       Date:  2015-10-29       Impact factor: 8.822

4.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

5.  C1 inhibitor deficiency: 2014 United Kingdom consensus document.

Authors:  H J Longhurst; M D Tarzi; F Ashworth; C Bethune; C Cale; J Dempster; M Gompels; S Jolles; S Seneviratne; C Symons; A Price; D Edgar
Journal:  Clin Exp Immunol       Date:  2015-05-13       Impact factor: 4.330

6.  Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study.

Authors:  Tomoya Hirose; Futoshi Kimbara; Masahiro Shinozaki; Yasuaki Mizushima; Hidehiko Yamamoto; Masashi Kishi; Takeyuki Kiguchi; Shigeru Shiono; Mitsuhiro Noborio; Akihiro Fuke; Hiroshi Akimoto; Takaaki Kimura; Shinichiro Kaga; Takahiko Horiuchi; Takeshi Shimazu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

7.  Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.

Authors:  Hilary J Longhurst; John Dempster; Lorena Lorenzo; Matthew Buckland; Sofia Grigoriadou; Christine Symons; Claire Bethune; Vincent Fabien; Catherine Bangs; Tomaz Garcez
Journal:  Allergy Asthma Clin Immunol       Date:  2018-08-06       Impact factor: 3.406

8.  Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Authors:  Elyse Murphy; Christine Donahue; Laurel Omert; Stephanie Persons; Thomas J Tyma; Joseph Chiao; William Lumry
Journal:  Nurs Open       Date:  2018-08-28

9.  Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.

Authors:  Anette Bygum; Teresa Caballero; Anete S Grumach; Hilary J Longhurst; Laurence Bouillet; Werner Aberer; Andrea Zanichelli; Jaco Botha; Irmgard Andresen; Marcus Maurer
Journal:  Clin Transl Allergy       Date:  2019-07-19       Impact factor: 5.871

10.  Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey.

Authors:  Aleena Banerji; Murat Baş; Jonathan A Bernstein; Isabelle Boccon-Gibod; Maria Bova; John Dempster; Anete Sevciovic Grumach; Markus Magerl; Kimberly Poarch; Manuel Branco Ferreira
Journal:  Allergy Rhinol (Providence)       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.